Scientists have also developed liposomes combined with an anti-EGFR aptamer (Apt) to target EGFR muted cancer cells using erlotinib (411) and later observed improvements in the reversal of hypoxia-induced resistance when they applied perfluorooctylbromide (PFOB) using the liposomal formulation (412). The gene discussed is EGFR; the disease is cancer.